Research programme: Hedgehog cell-signalling pathway stimulants - MAX BioPharma

Drug Profile

Research programme: Hedgehog cell-signalling pathway stimulants - MAX BioPharma

Alternative Names: Hedgehog signalling pathway activators - MAX BioPharma; Oxy 200; Oxy-133; Small molecule oxysterols - MAX BioPharma

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MAX BioPharma
  • Class Small molecules; Sterols
  • Mechanism of Action Hedgehog cell signalling pathway stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Osteoporosis

Highest Development Phases

  • Preclinical Non-union fracture; Osteoporosis

Most Recent Events

  • 12 Jul 2017 Research programme: Hedgehog cell-signalling pathway stimulants - MAX BioPharma is available for licensing as of 10 Jul 2017. www.maxbiopharma.com
  • 10 Jul 2017 Preclinical trials in Osteoporosis in USA (PO) before July 2017
  • 10 Jul 2017 Pharmacodynamics data of oxy 200 from a preclinical study in Osteoporosis released by MAX BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top